Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Prelude Therapeutics Inc’s stock clocked out at $1.05, up 2.94% from its previous closing price of $1.02. In other words, the price has increased by $2.94 from its previous closing price. On the day, 0.15 million shares were traded. PRLD stock price reached its highest trading level at $1.06 during the session, while it also had its lowest trading level at $0.99.
Ratios:
To gain a deeper understanding of PRLD’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.04 and its Current Ratio is at 7.04. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
On June 20, 2024, Barclays Downgraded its rating to Underweight which previously was Equal Weight but kept the price unchanged to $3.
On March 13, 2024, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $7.JMP Securities initiated its Mkt Outperform rating on March 13, 2024, with a $7 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 31 ’24 when Vaddi Krishna bought 5,000 shares for $1.21 per share. The transaction valued at 6,044 led to the insider holds 142,553 shares of the business.
Vaddi Krishna bought 10,000 shares of PRLD for $12,000 on Dec 30 ’24. The CEO now owns 137,553 shares after completing the transaction at $1.20 per share. On Dec 23 ’24, another insider, Combs Andrew, who serves as the Chief Chemistry Officer of the company, bought 60,000 shares for $1.37 each. As a result, the insider paid 82,002 and bolstered with 377,623 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRLD now has a Market Capitalization of 57786956 and an Enterprise Value of -77703072. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.26 while its Price-to-Book (P/B) ratio in mrq is 0.37. Its current Enterprise Value per Revenue stands at -25.901 whereas that against EBITDA is 0.549.
Stock Price History:
The Beta on a monthly basis for PRLD is 1.38, which has changed by -0.6818182 over the last 52 weeks, in comparison to a change of 0.23631513 over the same period for the S&P500. Over the past 52 weeks, PRLD has reached a high of $6.80, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is -2.64%, while the 200-Day Moving Average is calculated to be -67.23%.
Shares Statistics:
It appears that PRLD traded 483.39K shares on average per day over the past three months and 257590 shares per day over the past ten days. A total of 42.18M shares are outstanding, with a floating share count of 21.66M. Insiders hold about 60.64% of the company’s shares, while institutions hold 35.27% stake in the company. Shares short for PRLD as of 1735603200 were 3381616 with a Short Ratio of 7.00, compared to 1732838400 on 3056648. Therefore, it implies a Short% of Shares Outstanding of 3381616 and a Short% of Float of 19.5.
